Association of serum proteins S100A1, S100B, Zinc alpha glyco protein with components of metabolic syndrome in People with this syndrome

Abstract

Metabolic syndrome is a complicated multifactorial disease of modern life which has a progressive trend throughout the world. Based on evidence of disturbance in the secretion of some neurotrophins, such as S100A, S100B and the protein involved in regulating the metabolism of lipids (ZAG) are associated with elevated blood pressure and obesity. The aim of current study was also to determine the relationship between S100A, S100B, and ZAG proteins with metabolic syndrome components in people affected by this syndrome and also to compare these people with healthy people. Methods: In this study, the participants included 88 women and men with ages ranging from 30 to 50 years, 44 of them were affected by metabolic syndrome (MetS) (according to ATP (III)) and 44 healthy subjects. Anthropometric factors (weight, height, waist, and hips) were measured and body mass index (BMI) and waist to hips ration (WHR) were calculated. Blood pressure of all participants was measured and biochemical indices (blood glucose, TC, TG, LDL-C, HDL-C, insulin, insulin resistance, ZAG, S100A1, S100B) were evaluated. Results: Serum levels of S100A1 were significantly lower in the group with MetS than in the control group (P=0.008). However, Serum levels of S100B were significantly higher in the patient group than in the healthy group (P=0.001). Serum levels of ZAG in the patient group were also lower than the control group, which was not significant. In the whole population studied, there was a significant negative correlation between serum levels of S100A1 and S100B (P = 0.007, r = -0.28) in the whole population. Also, there was a significant positive correlation between serum levels of S100A1 and ZAG (p <0.01, r = 0.8) in the whole population studied. Conclusions: The results indicate that changes in the circulating level of S100A1 protein occur in MetS patients. So that serum levels of S100A1 were lower in patients with metabolic syndrome than in control subjects. The strong correlation between serum ZAG and S100A1 might suggest that production or release of these two proteins could be related mechanistically. On the other hand, serum levels of S100B increased in patients. Considering the limited studies, more researches are needed to evaluate the serum levels of these proteins in metabolic syndrome.